ENDRA Life Sciences Inc

NASDAQ:NDRAUnited States

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Contact Information

Headquarters

3600 Green Ct Ste 350ANN ARBOR, MI, United States 48105-2440

Phone

734-335-0468

Fax

302-655-5049

Executives

Chairman of the Board, Acting Chief Executive Officer

Alexander Tokman

Chief Financial Officer

Richard Jacroux

Chief Technology Officer

Michael Thornton

Independent Director

Louis Basenese

Independent Director

Anthony DiGiandomenico